Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells f

Go back to Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells f
Xenetic Biosciences, Inc. (NASDAQ: XBIO) Delayed: 1.93 -0.09 (4.46%)
Previous Close $2.02    52 Week High $5.20 
Open $2.03    52 Week Low $0.21 
Day High $2.04    P/E N/A 
Day Low $1.90    EPS $-0.01 
Volume 18,881